WCTF.org Transplant News

DALLAS, May 7 /PRNewswire/ -- The top of the Empire State Building. The base camp of Mount Everest. And next, Machu Picchu. James Chippendale is a leukemia survivor and co-founder of Love Hope Strength Foundation, an international charity hosting x-treme music concerts in high locations to raise funds for cancer centers worldwide.

In March of 2000, James was diagnosed with a very aggressive form of leukemia. His doctors gave him a 50% chance of survival but after three rounds of intense chemotherapy, radiation and a bone marrow transplant from a German donor, James came back healthier and stronger and ready to join the battle in helping those who helped him. Thus, he co-founded Love Hope Strength Foundation (LHSF) with musician and cancer survivor Mike Peters from The Alarm.

Through innovative concerts and climbs, LHSF, with chapters in the US, UK and Australia, provides critical funding for cancer centers worldwide so that ALL people have access to quality treatment and are given the best chance at survival. Founded in 2006, LHSF has already raised approximately $700,000 its first year and achieved:

-- In October 2007, 35 musicians, mountaineers, cancer survivors, and LHSF
supporters departed from Kathmandu for a monumental 14 day trek to Base
Camp of Mount Everest for an acoustic concert known as Everest Rocks,
the highest concert ever performed. Peters, Stray Cats drummer Slim
Jim Phantom, UK folk artist Nick Harper, Glenn Tillbrook of the Squeeze
and acclaimed MTV producer Alex Coletti are just a few of the music
luminaries who conquered Everest Rocks.
-- Famed MTV producer Alex Coletti documented the Everest Rocks event,
which VH1 Classic and MHD (MTV Hi-Definition Television) have just
agreed to air. In the near future, the documentary will also be
available for sale with proceeds benefiting the charity.
-- LHSF just confirmed their next x-treme music concert, Peru Rocks, at
Machu Picchu, October 8-17, 2008, with up to 100 trekkers to celebrate
their "Climb Back From Cancer(TM)."

James devotes a great deal of his time to "the cause" -- providing patients in need with the same opportunity that he had: access to quality doctors and funding for treatments and medications. He is available to discuss his experiences, the foundation, and the challenges behind obtaining proper cancer treatment. http://www.lovehopestrength.org/

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. James Chippendale http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=76642

First Call Analyst:
FCMN Contact:

Source: Love Hope Strength Foundation

CONTACT: Susan Friedman, +1-214-559-0122, susan@friedmanpr.com, for Love
Hope Strength Foundation

Web site:

http://www.lovehopestrength.org/

-------
Profile: Transplant News

RANCHO CORDOVA, Calif., May 7 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (NASDAQ:KOOL), a leading supplier of innovative products and services that process and store adult stem cells, today reported results for the third quarter and first nine months of fiscal 2008. Separately, the Company announced an Amended and Restated Distribution Agreement with General Electric Health Care (GEHC).

Revenues for the quarter ended March 31, 2008, were $5.6 million, an eight percent increase over revenues of $5.2 million in the same period a year ago. Total disposable revenues were $3.0 million, a 25 percent increase over disposable revenues of $2.4 million in the third quarter a year ago.

The Company reported a net loss of $2.7 million, or $0.05 per share, versus a net loss of $1.0 million, or $0.02 per share, in the same period a year ago. At March 31, 2008, the Company had $29 million in cash, cash equivalents and short-term investments. Total cancellable backlog at the end of the quarter was $4.3 million. This compares with $2.3 million in the same period a year ago and $3.9 million at the end of the most recent quarter.

"Our results for the quarter reflect the continued growth in sales of our AXP(TM) AutoXpress Platform (AXP) devices and disposable bag sets as we have continued to experience both increased demand and improved manufacturing yields," said Dr. William Osgood, the Company's Chief Executive Officer. The Company said it shipped 6 BioArchive devices during the quarter versus 7 in the same quarter a year ago.

"With respect to the voluntary recall of certain AXP bag sets that we announced in late February, I am pleased to report that as of now we have successfully reconditioned about 50 percent of the recalled bag set lots, all having passed the necessary pyrogen test with no exceptions," he added. "We expect to have completed our testing and reconditioning of the remaining available lots in the near future and are confident that all remaining lots will pass testing."

The Company said its gross margin was impacted by costs related to the recall. The increase in operating expenses was due primarily to legal expenses incurred in connection with the realignment of its distribution agreement with GEHC, increase in research and development expenses for work related to its Vantus(TM), Inc. subsidiary and costs associated with the newly created position of Chief Technology Architect that were not incurred in the prior year.

"As outlined in our other announcement today, we are delighted over our new relationship with GEHC. It enables us to maximize the value of our offerings, while continuing to pursue areas of mutual interest with them," Osgood said.

"We are very excited about the potential opportunities available to us with our MarrowXpress(TM) program, which is a version of our AutoXpress Platform targeted to the processing of bone marrow. We expect to receive a CE Mark in the very near future and are within days of filing our 510(k) submission to the FDA. We have identified several potential customers who plan to use the device in clinical trials and the practice of medicine in the areas of orthopedic surgery, cardiac ischemia and critical limb ischemia."

"We are also hitting our key milestones with our Vantus subsidiary, the stem cell laboratory services company we announced last quarter that is focused initially on the equine stem cell market. Our new collaboration with UC Davis is making rapid progress and we are now working with several breeders with an eye toward commencing full operations at Vantus at the beginning of calendar 2009," Osgood continued.

"With the realignment of the GEHC agreement and progress made on the recall, we have addressed two key issues impacting our business and are now focused on the many opportunities in regenerative medicine that are in front of us. We are continuing to drive our turnaround strategy by solidifying our current businesses and adapting our technologies to new and even larger markets," Osgood said.

For the first nine months of fiscal 2008, ThermoGenesis reported revenues of $14.8 million versus $13.2 million in the first nine months of fiscal 2007. Disposable revenues were $7.5 million, a 44 percent increase over disposable revenues of $5.2 million a year ago. The Company reported a net loss of $6.7 million, or $0.12 per share, compared with a net loss of $4.2 million, or $0.08 per share, in the same period a year ago.

With the continued successful fulfillment of our existing AXP disposables backlog and anticipated BioArchive sales, we believe we can realize close to our previously indicated fourth quarter revenue goal of $7 million, despite the transition resulting from our amended agreement with GEHC.

Conference call details:
Dial-in (U.S.): 1-800-860-2442
Dial-in (International): 412-858-4600
Conference name: "ThermoGenesis"

To listen to the audio webcast of the call during or after the event, please visit: http://www.thermogenesis.com/investor_relations/index.asp.

An audio replay of the conference call will be available beginning approximately two hours after completion of the call for the following five business days.

To access the reply:
Access number (U.S.): 877-344-7529
Access number (International): 412-317-0088
Conference ID#: "385107"

THERMOGENESIS CORP.
Condensed Consolidated Balance Sheets
(Unaudited)

March 31, June 30,
2008 2007
ASSETS
Current assets:
Cash and cash equivalents $11,152,000 $5,730,000
Short term investments 17,891,000 27,649,000
Accounts receivable, net 3,565,000 3,226,000
Inventories 4,662,000 5,046,000
Other current assets 243,000 415,000

Total current assets 37,513,000 42,066,000

Equipment, net 1,635,000 1,602,000
Other assets 73,000 122,000

$39,221,000 $43,790,000

LIABILITIES AND STOCKHOLDER'S EQUITY

Current liabilities:
Accounts payable $2,476,000 $2,074,000
Other current liabilities 2,592,000 2,233,000

Total current liabilities 5,068,000 4,307,000

Long-term liabilities 1,154,000 1,671,000

Stockholders' equity 32,999,000 37,812,000

$39,221,000 $43,790,000

THERMOGENESIS CORP.
Condensed Consolidated Statements of Operations
(Unaudited)

Three Months Ended Nine Months Ended
March 31, March 31,
2008 2007 2008 2007
Net revenues $5,645,000 $5,210,000 $14,764,000 $13,231,000

Cost of revenues 4,144,000 3,438,000 10,144,000 8,958,000

Gross profit 1,501,000 1,772,000 4,620,000 4,273,000

Expenses:
Selling, general
and administrative 2,550,000 2,201,000 7,327,000 6,813,000

Research and
development 1,902,000 1,034,000 5,015,000 2,969,000

Total operating
expenses 4,452,000 3,235,000 12,342,000 9,782,000

Interest and other
income, net 271,000 426,000 1,025,000 1,346,000

Net loss ($2,680,000)($1,037,000) ($6,697,000) ($4,163,000)

Basic and diluted net
loss per common share ($0.05) ($0.02) ($0.12) ($0.08)

Shares used in
computing per share
data 55,701,175 55,266,175 55,687,286 55,103,539

THERMOGENESIS CORP.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

Nine Months Ended
March 31,
2008 2007
Cash flows from operating activities:
Net loss ($6,697,000) ($4,163,000)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 402,000 347,000
Stock based compensation expense 1,618,000 614,000
Accretion of discount on short-term
investments (782,000) (969,000)
Loss on sale of equipment -- 9,000

Net change in operating assets and
liabilities:
Accounts receivable, net (339,000) (335,000)
Inventories 245,000 (1,911,000)
Other current assets 172,000 83,000
Other assets 49,000 (16,000)
Accounts payable 402,000 215,000
Accrued payroll and related
expenses (121,000) (93,000)
Deferred revenue (545,000) (102,000)
Other current liabilities 522,000 320,000
Net cash used in operating
activities (5,074,000) (6,001,000)

Cash flows from investing activities:
Capital expenditures (296,000) (328,000)
Purchase of investments (27,460,000) (37,743,000)
Maturities of investments 38,000,000 49,000,000
Net cash provided by investing
activities: 10,244,000 10,929,000

Cash flows from financing activities:
Payments on capital lease obligations (14,000) (13,000)
Exercise of stock options and warrants 266,000 1,140,000
Net cash provided by financing
activities 252,000 1,127,000
Net increase in cash and cash equivalents 5,422,000 6,055,000

Cash and cash equivalents at beginning
of period 5,730,000 3,527,000
Cash and cash equivalents at end of
period $11,152,000 $9,582,000

About ThermoGenesis Corp.

ThermoGenesis Corp. (http://www.thermogenesis.com/) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

-- The BioArchive(R) System, an automated cryogenic device, is used by
cord blood stem cell banks in more than 25 countries for cryopreserving
and archiving cord blood stem cell units for transplant. GE Healthcare
is the non-exclusive global distribution partner for the BioArchive
System.

-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of
automated devices that includes the AXP and the MarrowXpress(TM) and
companion sterile blood processing disposable for harvesting stem cells
in a closed system. The AXP device is used for the processing of cord
blood. GE Healthcare is the exclusive global distribution partner for
the AXP cord blood product. The MarrowXpress is used for isolating
stem cells from bone marrow. ThermoGenesis sells the MarrowXpress
directly to global customers.

-- The CryoSeal(R) FS System, an automated device and companion sterile
blood processing disposable, is used to prepare fibrin sealants from
plasma in about an hour. We received FDA approval to market the
CryoSeal FS System in liver resection surgeries in July 2007. The
CryoSeal FS System has received the CE-Mark. From a marketing
perspective, the CE Mark is the European equivalent to an FDA approval,
in that it allows sales of the product throughout the European
community. Asahi Medical is the exclusive distributor for the CryoSeal
System in Japan and the Company markets through independent
distributors in Europe and South America.

-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood
processing disposable that prepares activated thrombin from a small
aliquot of plasma in less than 30 minutes. The CE-Marked TPD is
currently being marketed in Europe by Biomet, Inc., subsidiary Biomet
Biologics, Medtronic, Inc. and independent distributors.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2008, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2008. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com/

Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com

First Call Analyst:
FCMN Contact: epoutre@thermogenesis.com

Source: ThermoGenesis Corp.

CONTACT: Investor Relations of ThermoGenesis Corp., +1-916-858-5107,
ir@thermogenesis.com

Web site:

http://www.thermogenesis.com/

-------
Profile: Transplant News

NEW AGREEMENT RETURNS BIOARCHIVE(R) SYSTEM SALES RIGHTS TO COMPANY, IMPROVES ECONOMICS OF AXP(TM) BAG SET BUSINESS

RANCHO CORDOVA, Calif., May 7 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (NASDAQ:KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that in partnership with GE Healthcare (GEHC) it has restructured its existing International Distribution Agreement to maximize the AXP product value utilizing each parties' respective strengths and focusing on long-term strategic goals.

Key elements of the revised agreement, which will become effective on July 1, 2008, include:

-- GEHC will continue as the exclusive distributor of AXP Platform
products as well as any future related products used in applications
based on volume reduction of blood derived from umbilical cord blood
and/or placenta outside of South America, Russia and China (excluding
Hong Kong and Taiwan).
-- GEHC will return worldwide rights to distribute the BioArchive System
to ThermoGenesis but for the time being GEHC will retain servicing
rights in North America and most of Europe.
-- Financial terms have been amended to better reflect each party's
contributions.

"This new agreement is a win-win for our current and prospective customers and ThermoGenesis shareholders. It also realigns our mutual interests with GEHC and will enable us to pursue other potential collaborations," said Dr. William Osgood, Chief Executive Officer of ThermoGenesis.

"We can now reengage our former BioArchive distributors -- many of whom have been distributing our other offerings -- and explore maximizing the market opportunities for our current and future offerings. At the same time, we will continue to work with GEHC to develop areas of mutual interest in regenerative medicine and look forward to identifying new technologies or markets that we can develop jointly," he added.

About ThermoGenesis Corp.

ThermoGenesis Corp. (http://www.thermogenesis.com/) is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury. These products include:

-- The BioArchive(R) System, an automated cryogenic device, is used by
cord blood stem cell banks in more than 25 countries for cryopreserving
and archiving cord blood stem cell units for transplant.
-- AXP(TM) AutoXpress(TM) System is used for the processing of cord blood
including sterile blood processing disposable for harvesting stem cells
in a closed system.
-- AXP(TM) MarrowXpress(TM) is used for isolating stem cells from bone
marrow in a closed system.
-- The CryoSeal(R) FS System, an automated device and companion sterile
blood processing disposable, is used to prepare fibrin sealants from
plasma in about an hour.
-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood
processing disposable that prepares activated thrombin from a small
aliquot of plasma in less than 30 minutes.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2008, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2008. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com/

Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com

First Call Analyst:
FCMN Contact: epoutre@thermogenesis.com

Source: ThermoGenesis Corp.

CONTACT: Investor Relations of ThermoGenesis Corp., +1-916-858-5107,
ir@thermogenesis.com

Web site:

http://www.thermogenesis.com/

-------
Profile: Transplant News

- CEO John Cassin Brings 30 Years of Business Experience To Vail Valley Medical Center

VAIL, Colo., May 7 /PRNewswire/ -- The Board of Directors of the Vail Valley Medical Center announced today the appointment of the new President and CEO, John H. Cassin. Cassin brings more than 30 years of healthcare leadership experience to the Vail Valley Medical Center.

"John brings great leadership experience and an engaging personal style, plus diverse health care knowledge and understanding to this critical position in charting the future of healthcare in our community," said Ron Davis, Chairman of the Vail Valley Medical Center Board of Directors.

"The VVMC Board is excited about John's demonstrated financial and strategic development skills, history of forging strong physician and community relationships and his commitment to the Vail Valley," Davis continued.

Cassin's business acumen ranges from integrated delivery system formations and multi-specialty physician group practices to health maintenance organizations and academic medical centers.

Cassin was instrumental in establishing a multitude of Centers of Excellence in the areas of: oncology, transplantation, orthopedics, cardio-thoracic technology, neuroscience and comprehensive women's services. He was also a key strategic leader and business developer of the Anschutz Medical Campus, a 600 acre, multi-billion dollar academic and clinical enterprise located in Aurora, Colo. The full scale development of this project is unprecedented in Colorado history.

Cassin's professional career has been predominately Colorado-based with the exception of various positions which led him abroad on government assignments. Cassin traveled extensively across central Asia as a healthcare consultant and participated in numerous humanitarian efforts. Cassin's travel took him to Uzbekistan, Turkmenistan, Kyrgyzstan and Tajikistan shortly after Operation Desert Storm.

Originally from New York, Cassin attended State University of New York at Plattsburgh, where he received a Bachelor of Science in Business Administration and later earned a Master of Science in Health Administration from the University of Colorado.

First Call Analyst:
FCMN Contact:

Source: Vail Valley Medical Center

CONTACT: Ronald Davis, Chairman of Vail Valley Medical Center Board of
Directors, +1-970-331-1658, ron@davisllc.com

-------
Profile: Transplant News

CAMBRIDGE, Mass., May 7 /PRNewswire-FirstCall/ -- Genzyme Corp. (NASDAQ:GENZ) reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound produced a meaningful impact on key clinical manifestations of Gaucher disease. The results highlight the potential of this compound to become an innovative treatment option for Gaucher disease.

Genzyme's Cerezyme(R) (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, is administered through intravenous infusions. The company is developing Genz-112638, a capsule taken orally, to provide a convenient treatment alternative for patients and to provide a broader range of treatment options for physicians.

The primary analysis period of the Phase 2 study of Genz-112638 is scheduled to conclude later this year, and the results for all trial participants will be available in the first quarter of 2009. The study included 26 adults with Type 1 Gaucher disease at medical centers in North America, South America, Europe and Israel. It was designed to evaluate the efficacy, safety and pharmacokinetics of the compound over one year. Nearly all study participants had completed six months of treatment when the preliminary analysis was conducted, and approximately half of the participants had completed one year of treatment.

The preliminary analysis showed that Genz-112638 produced promising efficacy results at six months and that these results continued to improve through one year of treatment:

-- At six months, spleen volumes had decreased from baseline by a mean of
27 percent among the 21 patients for whom data were available. Spleen
volumes had decreased by 40 percent among 11 patients with available
data at one year.

-- At six months, hemoglobin levels had increased from baseline by a mean
of 0.9 grams per deciliter of blood among 17 patients for whom data
were available. Hemoglobin levels had increased by 1.3 grams per
deciliter among 13 patients with available data at one year.

-- Platelet counts increased from baseline by a mean of 18 percent among
17 patients treated for six months and by 34 percent among 13 patients
with available data at one year.

-- Chitotriosidase levels decreased from baseline by a mean of 30 percent
at six months among 20 patients and by 50 percent among 12 patients
treated for one year. Chitotriosidase commonly serves as a biomarker
of Gaucher disease burden, allowing physicians to monitor patient
response to treatment.

These preliminary results are consistent with results observed for patients beginning enzyme replacement therapy.

The analysis showed that drug-related adverse events seen in the trial occurred in a small number of patients, were mild and transient in nature, and did not require any medical intervention. The drug-related adverse events were diarrhea, abdominal pain, tachycardia, and headache.

Genzyme is currently developing protocols for two Phase 3 trials that it expects to initiate early next year. One trial is expected to include untreated Gaucher patients, and the other is expected to include patients previously treated with Cerezyme.

"We have set a very high bar in trying to develop an oral therapy for Gaucher disease given the remarkable impact that Cerezyme has had," said David P. Meeker, M.D., Genzyme's president of Lysosomal Storage Disorder Therapeutics. "We are excited by the potential of Genz-112638. The data we collect from this study and from the Phase 3 program will provide guidance on the roles that this compound may play in treating and maintaining patients with Gaucher disease."

Genzyme reported the results from the preliminary analysis of the Phase 2 study of Genz-112638 at its Analyst Day meeting held today in Boston.

About Gaucher disease

Gaucher disease is an inherited condition affecting fewer than 10,000 people worldwide. People with Gaucher disease do not have enough of an enzyme that breaks down a certain type of fat molecule called glucocerebrosidase. As a result, cells fill up with the undigested fat in different parts of the body, primarily the liver, spleen and bone marrow. Accumulation of Gaucher cells may cause spleen and liver enlargement, anemia, excessive bleeding and bruising, bone disease and a number of other signs and symptoms. The most common form of Gaucher disease, Type 1, does not affect the brain or nervous system.

About Genz-112638

Genz-112638, a novel glucosylceramide analog given orally, is designed to inhibit the enzyme glucosylceramide synthase, which results in reduced production of glucocerebroside. Glucocerebrosidase is the substance that builds up in the cells and tissues of people with Gaucher disease. In preclinical studies, the molecule has shown high potency and specificity. Based on its mechanism of action, which is independent of genotype, Genz-112638 is a potential therapy for all patients with Type 1 Gaucher disease. Initiation of the Phase 2 study of Genz-112638 in Gaucher disease followed completion of an extensive pre-clinical research effort and a Phase 1 program that involved more than 120 subjects in three separate studies. In addition to Gaucher disease, there are a variety of other conditions including Fabry disease that can be caused by malfunctions in the pathway targeted by this molecule. The compound is exclusively licensed from the University of Michigan and was developed with James A. Shayman, M.D.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Safe-Harbor

This press release contains forward-looking statements regarding Genzyme's future business plans including, without limitation, statements about the potential uses and benefits of Genz-112638; when final results from the Phase 2 study will be available; and future clinical trial plans and potential uses of the data from such clinical trials. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: the actual timing of the completion of the analysis of clinical study results; Genzyme's ability to accurately understand and predict the outcome and impact of its clinical studies related to Genz-112638; Genzyme's ability to continue to support its clinical and other development efforts related to Genz-112638; the actual efficacy and safety of Genz-112638; the outcome of discussions with regulatory authorities regarding clinical studies of Genz-112638; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the year ended December 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Cerezyme(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com/ and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:
Bo Piela Patrick Flanigan
(617) 768-6579 (617) 768-6563

First Call Analyst:
FCMN Contact:

Source: Genzyme Corp.

CONTACT: Media, Bo Piela, +1-617-768-6579, or Investors, Patrick
Flanigan, +1-617-768-6563, both of Genzyme Corp.

Web site:

http://www.genzyme.com/

Company News On-Call:

http://www.prnewswire.com/comp/104284.html

-------
Profile: Transplant News

Record number of Presentations

MOUNT LAUREL, N.J., May 7 /PRNewswire-USNewswire/ -- The eighth annual American Transplant Congress 2008 (ATC) is the most comprehensive, in-depth educational event in the field of basic and clinical transplantation science and medicine. This year, there will be a record number of presentations occurring over the five meeting days. With more than 1,700 presentations, both oral and poster, ATC 2008 is one of the most important transplantation conferences ever. The meeting is also on pace for a record number of attendees, who will gather at The Metropolitan Toronto Convention Centre in Toronto, Ontario from Saturday, May 31 - Wednesday, June 4, 2008.

2008 also marks the 50th anniversary of the first successful Canadian transplant and fittingly, the meeting travels to Canada for the first time.

The goal of this joint meeting, presented by the American Society of Transplant Surgeons (ASTS), and the American Society of Transplantation (AST), is to contribute to and expound upon new worldwide research and discoveries in transplantation.

Beginning on Sunday, controversial topics and new developments will be the focus of the Sunrise Symposia. There will be a joint plenary session held daily, with the top scoring abstracts presented to the entire attendee audience. On Sunday and Monday, there will be four, concurrent mid-day symposia centered on the most timely and topical issues in the field. The ever popular, "What's Hot, What's New" will be the feature presentation on Wednesday. Early morning workshops will run daily, Sunday - Wednesday, focusing on some of the best contributions in transplantation.

ATC 2008 Feature Topics & Highlights:

50th Anniversary Celebration - 1st Canadian Transplant, with special invited guests

State-of-the-Art Address - Tak Mak, PhD, Princess Margaret Hospital, Toronto, Ontario

State-of-the-Art Address - Luc Noel, PhD, World Health Organization
Special Interactive Session - Renal Transplant
"What's Hot, What's New" Presentation
Living Donation
NanoMedicine: Can Tiny Devices Solve Big Problems?
Infectious Diseases
Cardiac Risks
Minority Access
Stem Cell Research
Ethics and Economics
...and hundreds of other critical presentations

For more information about the American Society of Transplant Surgeons visit www.asts.org.

Learn more about the American Society of Transplantation at www.a-s-t.org.

Visit www.atcmeeting.org for details; meeting schedule, speakers, and more.

Media interviews can be arranged. If interested, contact Steven Schiff
610-971-4840; steve@schiffmarketing.com.
First Call Analyst:
FCMN Contact:

Source: American Transplant Congress 2008

CONTACT: Steven Schiff, Press Director for the American Transplant
Congress 2008, +1-610-971-4840, steve@schiffmarketing.com

Web Site:

http://www.a-s-t.org/
http://www.asts.org/
http://www.atcmeeting.org/

-------
Profile: Transplant News

ROCKVILLE, Md., May 7 /PRNewswire-FirstCall/ -- Stem cell company Neuralstem, Inc. (AMEX:CUR) is filing suit today against StemCells, Inc. stating, among other things, that StemCells intentionally withheld crucial information highly material to the patentability of StemCells' "new" patent (US Pat No. 7,361,505) and that this was done with the intent to deceive the United States Patent Office in order to get the '505 patent allowed. As a result of these actions, Neuralstem is asking for a declaratory judgment that the patent is unenforceable. The suit will be filed in the United States District Court for the District of Maryland Southern Division.

(Logo:

http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

"While we believe that it is clear that we are not infringing this patent, and we have not yet been directly accused by StemCells, Inc. of infringing this patent, the threatening statements in their press release of April 23rd leave the misleading impression that we would require a license from them as a result of the issuance of this patent. Nothing could be further from the truth," said Neuralstem President & CEO Richard Garr. "And, in addition to finding that the patent is unenforceable against us, or anyone else for that matter, as a result of their actions, we are asking that the Court also declare that we are not infringing the patent and that the patent is also invalid."

"We are confident that their intentional withholding of highly material information and their intent to deceive the Patent Office, will result in this patent being unenforceable," concluded Garr.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.

The company has also developed immortalized human neural stem cells for in-vitro use in drug development for the academic and pharmaceutical markets. For further information, please visit http://www.neuralstem.com/.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the quarterly report on Form 10-KSB for the year ended December 31, 2007.

First Call Analyst:
FCMN Contact:

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO
AP Archive:

http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Neuralstem, Inc.

CONTACT: Company Contact: Richard Garr, President, Neuralstem, Inc.,
+1-301-366-4960; Media: Deanne Eagle, Planet Communications, +1-917-837-5866;
Investor Relations: Ira Weingarten, +1-805-897-1880, or Steve Chizzik,
+1-908-688-9111, both of Equity Communications, all for Neuralstem, Inc.

Web site:

http://www.neuralstem.com/

-------
Profile: Transplant News

STAINES, England, May 7/PRNewswire/ -- The European Medicines Agency (EMEA) has announced the marketing
authorisation of Mycamine(R), Astellas Pharma Europe's treatment for invasive
candidiasis, oesophageal candidiasis and prophylaxis of Candida infection in
patients undergoing allogeneic haematopoietic stem cell transplantation.
Mycamine(R) will initially be available in the U.K and across the European
market shortly after this.

Professor David Denning of The University of Manchester said of the
announcement: "The approval of micafungin is very good news for patients with
life-threatening fungal infections in Europe. The Company has conducted a
number of large, high quality clinical studies in Candida infections with
impressive results. Particularly welcome are the indications for fungal
infections in children and babies, often a neglected group in the early drug
approval process."

The efficacy and safety of Mycamine(R) have been demonstrated in a
clinical development programme including more than 3,500 patients in 16
clinical trials. The trials included nearly 300 children. Mycamine(R) was
launched in Japan in 2002 and in the US three years ago. In these two major
markets more than 350,000 patients have been treated with the product.

"We are delighted that Mycamine(R) is now licensed for use in Europe,"
said Alan Houston, MBBS, MRCP, FFPM, Senior Vice President, Research and
Development, Astellas Pharma Europe. "It means that doctors will now have a
new option to treat both their adult and paediatric - including neonatal -
patients with."

Recognising the increasing need for new products to fight the growing
epidemic caused by healthcare associated infections, Astellas is committed to
building a strong anti-infectives franchise. This is reflected by its
extensive clinical trial programme which has been very positively received by
key opinion leaders in the area.

Notes to Editors

Mycamine

The indications for adults, adolescents 16 years of age or older and
elderly are: Treatment of invasive candidiasis; Treatment of oesophageal
candidiasis in patients for whom intravenous therapy is appropriate;
Prophylaxis of Candida infection in patients undergoing allogeneic
haematopoietic stem cell transplantation or patients who are expected
to have neutropenia (absolute neutrophil count < 500 cells / microlitre)
for 10 or more days. For children (including neonates) and
adolescents <16 years of age, Mycamine is indicated for: Treatment of
invasive candidiasis; Prophylaxis of Candida infection in patients
undergoing allogeneic haematopoietic stem cell transplantation or patients
who are expected to have neutropenia (absolute neutrophil count <500 cells
/ microlitre) for 10 or more days.

Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary
of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceutical products. The
organisation is committed to becoming a global category leader by combining
outstanding R&D and marketing capabilities and continuing to grow in the
world pharmaceutical market. In Europe, Astellas markets products in the
areas of Immunology, Urology, Dermatology and Cancer. Astellas Pharma Europe
has 20 affiliate offices located across Europe, the Middle East and Africa,
one R&D site and three manufacturing plants with nearly 3000 staff.

Astellas Pharma Europe Ltd., Lovett House, Lovett Road,
Staines, Middlesex TW18 3AZ

For more information please contact:
Mindy Dooa
Astellas Pharma Europe
Tel: +44(0)1784-419-408
Email: mindy.dooa@eu.astellas.com

Rosie Allan
Red Door Communications
Tel: +44(0)20-8392-6931
Email: rallan@rdcomms.com

Jas Kaur
Red Door Communications
Email: jkaur@rdcomms.com

Source: Astellas Pharma Europe Limited

For more information please contact: Mindy Dooa, Astellas Pharma Europe, Tel: +44(0)1784-419-408, Email: mindy.dooa@eu.astellas.com; Rosie Allan, Red Door Communications, Tel: +44(0)20-8392-6931, Email: rallan@rdcomms.com; Jas Kaur, Red Door Communications, Email: jkaur@rdcomms.com

-------
Profile: Transplant News